[Therapeutic drug monitoring of mycophenolate mofetil, sirolimus and cyclosporine at C2].
The evolutions in treatments and clinical practices in organ transplantations led to modifications in the therapeutic drug monitoring (TDM) of immunosuppressive drugs. A focus is made regarding the C2 sampling of cyclosporin, as well as the TDM of mycophenolate mofetil and sirolimus. A review of literature about the evolution of drug monitoring, technical methods and sampling strategies is described. Arguments in favour of TDM are thus a decrease in the frequency of both graft rejection and adverse drug reactions, however, new strategies or new targets are needed in new associations or indications.
Royer
B
B
Laboratoire de pharmacologie clinique, CHU Jean Minjoz, boulevard Fleming, 25030 Besançon. bernard.royer@ufc-chu.univ-fcomte.fr
Davani
S
S
Bérard
M
M
Kantelip
J-P
JP
Muret
P
P
D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid; D016572:Cyclosporine / Q000493:pharmacokinetics*; D016903:Drug Monitoring / Q000379:methods* / Q000592:standards; D017248:Enzyme Multiplied Immunoassay Technique; D006084:Graft Rejection; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics*; D016030:Kidney Transplantation; D016031:Liver Transplantation; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D018579:Patient Selection; D015203:Reproducibility of Results; D020123:Sirolimus / Q000493:pharmacokinetics*; D013997:Time Factors; D014181:Transplantation Immunology
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D020123:Sirolimus